Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.53 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.45 |
| ▸ | MERTK | Q12866 | 2/20 | 0.44 |
| ▸ | AXL | P30530 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.44 |
| ▸ | GAS6 | Q14393 | 1/20 | 0.44 |
| ▸ | GPR39 | O43194 | 2/20 | 0.42 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31097790 | 1.00 | EGFR (0.53) | EGFRMAPK3MERTKAXLFLT3 | |
| SCHEMBL25311865 | 0.99 | EGFR (0.51) | EGFRMAPK3MERTKAXLFLT3 | |
| SCHEMBL31097830 | 0.99 | EGFR (0.51) | EGFRMAPK3MERTKAXLFLT3 | |
| SCHEMBL31097817 | 0.87 | TYRO3 (0.41) | EGFRMAPK3MERTKAXLFLT3 | |
| SCHEMBL25316844 | 0.87 | TYRO3 (0.41) | EGFRMAPK3MERTKAXLFLT3 | |
| SCHEMBL25314530 | 0.84 | EGFR (0.52) | EGFRMAPK3ALDH1A1MAPTKMT2A | |
| SCHEMBL31097853 | 0.81 | EGFR (0.50) | EGFRMAPK3KDRKDM4E | |
| SCHEMBL25311938 | 0.81 | EGFR (0.50) | EGFRMAPK3KDRKDM4E | |
| SCHEMBL25876838 | 0.81 | TGM2 (0.43) | EGFR | |
| SCHEMBL25312918 | 0.77 | CCNK (0.47) | EGFRCCNKCDK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074889-A1 | Novel Aminobenzene Derivative Having Cancer Cell Growth Inhibitory Effect, and Preventive or Therapeutic Pharmaceutical Composition Containing Same as Active Ingredient | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2025-03-06 | — | — | US | claimed |
| EP-4464693-A1 | NOVEL AMINOBENZENE DERIVATIVE HAVING CANCER CELL GROWTH INHIBITORY EFFECT, AND PREVENTIVE OR THERAPEUTIC PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | Daewoong Pharmaceutical Co., Ltd. (KR) | 2024-11-20 | — | — | EP | claimed |
| WO-2023136645-A1 | NOVEL AMINOBENZENE DERIVATIVE HAVING CANCER CELL GROWTH INHIBITORY EFFECT, AND PREVENTIVE OR THERAPEUTIC PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | 주식회사 대웅제약 | 2023-07-20 | — | — | WO | claimed |
| US-20250074889-A1 | Novel Aminobenzene Derivative Having Cancer Cell Growth Inhibitory Effect, and Preventive or Therapeutic Pharmaceutical Composition Containing Same as Active Ingredient | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2025-03-06 | — | — | US | disclosed |
| EP-4464693-A1 | NOVEL AMINOBENZENE DERIVATIVE HAVING CANCER CELL GROWTH INHIBITORY EFFECT, AND PREVENTIVE OR THERAPEUTIC PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | Daewoong Pharmaceutical Co., Ltd. (KR) | 2024-11-20 | — | — | EP | disclosed |
| WO-2023136645-A1 | NOVEL AMINOBENZENE DERIVATIVE HAVING CANCER CELL GROWTH INHIBITORY EFFECT, AND PREVENTIVE OR THERAPEUTIC PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | 주식회사 대웅제약 | 2023-07-20 | — | — | WO | disclosed |
| WO-2023136645-A1 | NOVEL AMINOBENZENE DERIVATIVE HAVING CANCER CELL GROWTH INHIBITORY EFFECT, AND PREVENTIVE OR THERAPEUTIC PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | 주식회사 대웅제약 | 2023-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074889-A1 | Novel Aminobenzene Derivative Having Cancer Cell Growth Inhibitory Effect, and Preventive or Therapeutic Pharmaceutical Composition Containing Same as Active Ingredient | MKI67, CCNB1, ALDH7A1 | EGFR 69/4885MAPK3 441/4885MERTK 2468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.